INM
InMed Pharmaceuticals Inc.
NASDAQ · CAHealthcareBiotechnology
$1.52-1.30%
Price as of Jul 20, 2026
INM growth
InMed Pharmaceuticals Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -18.3%
- EBITDA
- -22.2%
- EBIT
- -22.8%
- EPS
- —
- Free cash flow
- -28.3%
- Operating cash flow
- -28.3%
Forward estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +65.5%
- EBITDA
- -2.7%
- EBIT
- +2.7%
- Net income
- -6.3%
- EPS
- +58.5%
- Free cash flow
- -11.0%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.